Tarsus Pharmaceuticals Inc (TARS) — Cash Flow-to-Debt Ratio
Tarsus Pharmaceuticals Inc (TARS) has a Cash Flow-to-Debt Ratio of -0.11x as of March 2026, meaning its operating cash flow of $-24.65 Million could theoretically repay 0% of its total liabilities ($232.18 Million) in one year. See free cash flow generation of Tarsus Pharmaceuticals Inc to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Tarsus Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2018–2025)
Historical debt coverage capacity for Tarsus Pharmaceuticals Inc across 8 annual periods. Also explore net asset growth rate of Tarsus Pharmaceuticals Inc to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Tarsus Pharmaceuticals Inc (2018–2025)
Year-by-year debt coverage analysis for Tarsus Pharmaceuticals Inc. For market capitalisation and broader financial context, see TARS stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.06x | $-12.45 Million | $218.73 Million | ▲ +89.5% |
| 2024 | -0.54x | $-83.03 Million | $152.46 Million | ▲ +68.2% |
| 2023 | -1.72x | $-117.49 Million | $68.50 Million | ▼ -22.3% |
| 2022 | -1.40x | $-49.03 Million | $34.96 Million | ▼ -555.6% |
| 2021 | 0.31x | $3.75 Million | $12.18 Million | ▲ +108.7% |
| 2020 | -3.53x | $-21.14 Million | $5.99 Million | ▼ -6077.7% |
| 2019 | -0.06x | $-3.67 Million | $64.32 Million | ▲ +81.9% |
| 2018 | -0.32x | $-1.18 Million | $3.74 Million | — |